Amid its global push to reach more patients with SGLT2 inhibitor Jardiance, Boehringer Ingelheim reported solid sales growth for the med last year. Now, armed with two new FDA approvals in a span of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results